Adults with a cannabis-related acute care visit or hospitalization were at 23% and 72% greater risk of a new dementia diagnosis within 5 years, a new study finds.
In addition to support for phase 3 CLARITY AD findings, new evidence was presented supporting lecanemab safety and efficacy in ApoE ε4 carriers and non-carriers.